Cerebral Vein Thrombosis Treatment Market
Cerebral Vein Thrombosis Treatment Market by Treatment, Drug Class, End Use & Region | Forecast 2023 to 2033
Market Insights on Cerebral Vein Thrombosis Treatment covering sales outlook, demand forecast and up-to-date key trends
Cerebral Vein Thrombosis Treatment Market Snapshot (2023 to 2033)
The global cerebral vein thrombosis treatment market garnered a market value of US$ 170.55 million in 2022 and is expected to accumulate a market value of US$ 611 million by registering a CAGR of 12.3% in the forecast period 2023 to 2033. The growth of the cerebral vein thrombosis treatment market can be attributed to growing demand for more effective treatments for CVT due to an increasing incidence of the condition and the serious nature of its potential complications. The market for cerebral vein thrombosis treatment registered a CAGR of 6.7% in the historical period 2018 to 2022.
Cerebral vein thrombosis (CVT) is a rare but serious medical condition in which a blood clot forms in the veins that drain blood from the brain. CVT can lead to a range of symptoms, including headache, vision changes, seizures, and stroke.
The treatment of CVT depends on the severity of the condition and the specific symptoms experienced by the patient. In general, treatment may involve the use of anticoagulant medications to prevent the formation of additional blood clots and to dissolve existing clots. Thrombolytic therapy, which involves the use of drugs to break down blood clots, may also be used in some cases.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 191.53 Million |
|
Anticipated Forecast Value (2033) |
US$ 611 Million |
|
Projected Growth Rate (2023 to 2033) |
12.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Cerebral Vein Thrombosis Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Cerebral vein thrombosis treatment reflected a value of 6.7% during the historical period, 2018 to 2022.
During this time, there has been a growing awareness of CVT among healthcare professionals, leading to improved diagnosis and treatment of the condition. Additionally, the development of new drugs and therapies, such as direct oral anticoagulants (DOACs), has improved the efficacy of treatment and expanded the options available to patients.
Overall, the cerebral vein thrombosis treatment market is expected to continue to grow in the coming years due to factors such as increasing awareness and advances in treatment options. Thus, the market for Cerebral vein thrombosis treatment is expected to register a CAGR of 12.3% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Cerebral Vein Thrombosis Treatment Market?
Increasing incidence of CVT along with Advances in treatment options driving market growth
While CVT is a rare condition, the incidence of the disease has been increasing in recent years, which has led to a growing demand for effective treatments. Increased awareness of the symptoms and risk factors of CVT among healthcare professionals and patients has led to earlier diagnosis and improved treatment outcomes.
The development of new drugs and therapies, such as DOACs, has expanded the range of treatment options available to patients, improving the efficacy of treatment and patient outcomes. The aging population is more susceptible to CVT, and as the population continues to age, the demand for treatment for CVT is likely to increase.
The increasing healthcare expenditure in many countries has led to increased funding for research and development of new treatments for CVT. Advances in medical technology, such as endovascular treatment, have improved the efficacy of treatment and expanded the options available to patients.
Availability of treatments shaping landscape for cerebral vein thrombosis treatment market
Anticoagulation therapy: This involves the use of blood-thinning medications such as heparin and warfarin to prevent further blood clots from forming and to dissolve existing clots.
Endovascular treatment: This is a minimally invasive procedure that involves the use of a catheter to remove or dissolve blood clots in the veins of the brain.
Steroids: In some cases, corticosteroids may be used to reduce inflammation and swelling in the brain.
Management of underlying conditions: Treating underlying conditions that contribute to the development of CVT, such as cancer or infections, can also be an important part of treatment.
Supportive care: Patients with CVT may require supportive care such as fluids, oxygen, and medications to control symptoms such as headaches and seizures.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Cerebral Vein Thrombosis Treatment Market?
Limited awareness and diagnosis along with High cost of treatment derailing market growth
While awareness of CVT has been increasing, many cases still go undiagnosed or misdiagnosed, leading to delayed treatment and poorer outcomes. The cost of treatment for CVT can be high, particularly for newer drugs and therapies, which may limit access to treatment for some patients.
Anticoagulant therapy, which is a common treatment for CVT, carries a risk of bleeding, and other treatments may also have adverse effects. CVT is a rare condition, and research and development efforts may be limited compared to more common diseases.
There is currently no standardized treatment protocol for CVT, and treatment may vary depending on the location and severity of the clot, as well as other factors. Many patients with CVT have other underlying medical conditions that may complicate treatment and increase the risk of adverse outcomes. thus, the aforementioned factors are derailing the market growth of cerebral vein thrombosis treatment.
Region-Wise Insights
Growing Prevalence of CVT Bolstering Market for Treatment in North America?
Increasing awareness of CVT propelling demand for CVT treatment market
The North America cerebral vein thrombosis treatment market has seen significant growth in recent years, driven by factors such as an increasing incidence of CVT, improved awareness and diagnosis, and the availability of new and effective treatments.
Factors such as increasing healthcare expenditure, growing awareness of the disease, and the availability of advanced medical technologies as drivers of market growth. In terms of treatment options, the North American market offers a range of anticoagulants, endovascular therapies, and other treatments that are used to manage CVT. There is also ongoing research into new treatments and diagnostic tools, which is expected to drive further growth in the market in the coming years.
Overall, the North American cerebral vein thrombosis treatment market is expected to continue to grow as a result of a combination of demographic, economic, and technological factors that are driving demand for effective and innovative treatments for this rare but serious condition. Thus, North America is expected to possess a 44% market share for cerebral vein thrombosis treatment in 2023.
Extensive Research and Development Creating Lucrative Opportunities for CVT Treatment in Europe?
Presence of state-of-the-art medical technologies contributing to market growth in Europe
Factors such as increasing healthcare expenditure, growing awareness of the disease, and the availability of advanced medical technologies as drivers of market growth.
In terms of treatment options, the European market offers a range of anticoagulants, endovascular therapies, and other treatments that are used to manage CVT. In addition, several European countries have developed national guidelines for the management of CVT, which have helped to standardize treatment protocols and improve patient outcomes.
There is also ongoing research into new treatments and diagnostic tools in Europe, which is expected to drive further growth in the market in the coming years. For example, the European Society of Neurology has established a working group to develop guidelines for the diagnosis and treatment of CVT, which will help to improve the standard of care for patients with this condition. Thus, Europe is expected to possess a 41% market share for cerebral vein thrombosis treatment in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Access to Specialized Medical Staff Making Hospitals and Clinics a Likeable Option for CVT Treatment?
Accessibility to advanced diagnostic and treatment tools favoring growth of hospitals and clinics for CVT treatment
Hospitals and clinics are typically the best places to receive cerebral vein thrombosis treatment because they have the necessary resources, expertise, and facilities to manage this complex condition. Hospitals and clinics typically have specialized medical staff who are trained to manage CVT, including neurologists, neurosurgeons, and interventional radiologists.
Hospitals and clinics have access to advanced diagnostic tools, such as MRI and CT scans, which can be used to diagnose and monitor CVT. They also have access to a range of treatment options, including anticoagulants and endovascular therapies.
CVT can be a medical emergency, and hospitals and clinics have emergency departments that are equipped to handle acute cases of CVT. Hospitals and clinics often have a multidisciplinary team that works together to manage CVT patients, including doctors, nurses, physical therapists, and other healthcare professionals.
CVT treatment often requires ongoing monitoring and follow-up care, which hospitals and clinics are equipped to provide. Thus, hospitals and clinics are expected to possess a 46% market share for CVT treatment market in 2023.
Market Competition
Key players in the cerebral vein thrombosis treatment market are Boston Scientific Corporation, AngioDynamics, Cardinal Health, Daesung Maref, Johnson & Johnson Services, Inc., Neuland Laboratories Ltd, Glenmark Pharmaceuticals Inc., Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation and Portola Pharmaceuticals, Inc.
- Boston Scientific Corporation has designed Vici Venous Stent System to treat patients with chronic deep vein obstruction in the iliofemoral vein. This stent system has been shown to be effective in the management of venous outflow obstruction, which is a common complication of CVT.
- Cardinal Health's key products in for CVT treatment is the Argyle™ Thrombectomy System, which is a catheter-based device used in the removal of blood clots from the veins. This system can be used in the treatment of CVT to remove blood clots that are causing a blockage in the cerebral veins.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 191.53 Million |
|
Market Value in 2033 |
US$ 611 Million |
|
Growth Rate |
CAGR of 12.3% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Cerebral Vein Thrombosis Treatment Industry Survey
Treatment:
- Thrombolytic Therapy
- Anticonvulsant Therapy
Drug Class:
- Thalidomide
- Tamoxifen
- Phytoestrogens
- L-asparaginase
End Use:
- Hospitals & Clinics
- Laboratories
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
Why is the United States Market Witnessing Higher Growth?
The rising awareness of CVT treatment is fueling the demand in the United States.
What is the Valuation of the Cerebrel Vein Thrombosis Treatment Market in 2023?
The global market is estimated to register a valuation of US$ 191.53 million in 2023.
What is Driving the Adoption of Cerebrel Vein Thrombosis Treatment Globally?
The rising advanced treatment options has necessitated virtualization security.
What will be the Contribution of North America in the Global Market?
North America hold a share of 44% in the global market by 2033.
Which Region Presents Lucrative Growth Opportunities?
North America to witness lucrative growth opportunities through 2033.
Table of Content
1. Executive Summary | Cerebral Vein Thrombosis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Thrombolytic Therapy 5.3.2. Anticonvulsant Therapy 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 6.3.1. Thalidomide 6.3.2. Tamoxifen 6.3.3. Phytoestrogens 6.3.4. L-asparaginase 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2023 to 2033 7.3.1. Hospitals & Clinics 7.3.2. Laboratories 7.4. Y-o-Y Growth Trend Analysis By End-use, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-use, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Drug Class 9.2.4. By End-use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Drug Class 9.3.4. By End-use 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Drug Class 10.2.4. By End-use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Drug Class 10.3.4. By End-use 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Treatment 11.2.3. By Drug Class 11.2.4. By End-use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Drug Class 11.3.4. By End-use 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Treatment 12.2.3. By Drug Class 12.2.4. By End-use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Drug Class 12.3.4. By End-use 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment 13.2.3. By Drug Class 13.2.4. By End-use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Drug Class 13.3.4. By End-use 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Treatment 14.2.3. By Drug Class 14.2.4. By End-use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Drug Class 14.3.4. By End-use 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Treatment 15.2.3. By Drug Class 15.2.4. By End-use 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment 15.3.3. By Drug Class 15.3.4. By End-use 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Treatment 16.1.2.2. By Drug Class 16.1.2.3. By End-use 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Treatment 16.2.2.2. By Drug Class 16.2.2.3. By End-use 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Treatment 16.3.2.2. By Drug Class 16.3.2.3. By End-use 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Treatment 16.4.2.2. By Drug Class 16.4.2.3. By End-use 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Treatment 16.5.2.2. By Drug Class 16.5.2.3. By End-use 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Treatment 16.6.2.2. By Drug Class 16.6.2.3. By End-use 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Treatment 16.7.2.2. By Drug Class 16.7.2.3. By End-use 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Treatment 16.8.2.2. By Drug Class 16.8.2.3. By End-use 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Treatment 16.9.2.2. By Drug Class 16.9.2.3. By End-use 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Treatment 16.10.2.2. By Drug Class 16.10.2.3. By End-use 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Treatment 16.11.2.2. By Drug Class 16.11.2.3. By End-use 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Treatment 16.12.2.2. By Drug Class 16.12.2.3. By End-use 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Treatment 16.13.2.2. By Drug Class 16.13.2.3. By End-use 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Treatment 16.14.2.2. By Drug Class 16.14.2.3. By End-use 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Treatment 16.15.2.2. By Drug Class 16.15.2.3. By End-use 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Treatment 16.16.2.2. By Drug Class 16.16.2.3. By End-use 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Treatment 16.17.2.2. By Drug Class 16.17.2.3. By End-use 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Treatment 16.18.2.2. By Drug Class 16.18.2.3. By End-use 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Treatment 16.19.2.2. By Drug Class 16.19.2.3. By End-use 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Treatment 16.20.2.2. By Drug Class 16.20.2.3. By End-use 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Treatment 16.21.2.2. By Drug Class 16.21.2.3. By End-use 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Treatment 17.3.3. By Drug Class 17.3.4. By End-use 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Boston Scientific Corporation 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. AngioDynamics 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Cardinal Health 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Daesung Maref 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Johnson & Johnson Services, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Neuland Laboratories Ltd 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Glenmark Pharmaceuticals Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Momenta Pharmaceuticals 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Mitsubishi Tanabe Pharma Corporation 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Portola Pharmaceuticals, Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by End-use, 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by End-use, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End-use, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 18: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 19: Global Market Attractiveness by End-use, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End-use, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 38: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 39: North America Market Attractiveness by End-use, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End-use, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End-use, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by End-use, 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 77: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 78: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 79: Europe Market Attractiveness by End-use, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by End-use, 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 97: South Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 99: South Asia Market Attractiveness by End-use, 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by End-use, 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 117: East Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 119: East Asia Market Attractiveness by End-use, 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by End-use, 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 137: Oceania Market Attractiveness by Treatment, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 139: Oceania Market Attractiveness by End-use, 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by End-use, 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by End-use, 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by End-use, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-use, 2023 to 2033 Figure 157: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 158: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 159: MEA Market Attractiveness by End-use, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
